Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11937
Title: Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre.
Austin Authors: Sia, Joseph;Joon, Daryl Lim;Viotto, Angela ;Mantle, Carmel;Quong, George;Rolfo, Aldo;Wada, Morikatsu ;Anderson, Nigel;Rolfo, Maureen;Khoo, Vincent
Affiliation: Radiation Oncology
Issue Date: 1-Sep-2011
Publication information: Cancers 2011; 3(3): 3419-31
Abstract: To report the toxicity and long-term outcomes of dose-escalated intensity-modulated radiation therapy (IMRT) for patients with localised prostate cancer.From 2001 to 2005, a total of 125 patients with histologically confirmed T1-3N0M0 prostate cancer were treated with IMRT to 74Gy at the Austin Health Radiation Oncology Centre. The median follow-up was 5.5 years (range 0.5-8.9 years). Biochemical prostate specific antigen (bPSA) failure was defined according to the Phoenix consensus definition (absolute nadir + 2ng/mL). Toxicity was scored according to the RTOG/EORTC criteria. Kaplan-Meier analysis was used to calculate toxicity rates, as well as the risks of bPSA failure, distant metastases, disease-specific and overall survival, at 5 and 8-years post treatment.All patients completed radiotherapy without any treatment breaks. The 8-year risks of ≥ Grade 2 genitourinary (GU) and gastrointestinal (GI) toxicity were 6.4% and 5.8% respectively, and the 8-year risks of ≥ Grade 3 GU and GI toxicity were both < 0.05%. The 5 and 8-year freedom from bPSA failure were 76% and 58% respectively. Disease-specific survival at 5 and 8 years were 95% and 91%, respectively, and overall survival at 5 and 8 years were 90% and 71%, respectively.These results confirm existing international data regarding the safety and efficacy of dose-escalated intensity-modulated radiation therapy for localised prostate cancer within an Australian setting.
URI: https://ahro.austin.org.au/austinjspui/handle/1/11937
DOI: 10.3390/cancers3033419
ORCID: 
Journal: Cancers
URL: https://pubmed.ncbi.nlm.nih.gov/24212961
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

46
checked on Jul 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.